Participant flow

Study of Bendamustine and IXAZOMIB (MLN9708) Plus Dexamethasone in Relapsed/Refractory Multiple Myeloma · Source last updated 2020-10-22

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups

1. description

   MLN9708 : 4 mg, days 1, 8, 15. Dexamethasone: 40 mg oral weekly. Bendamustine: 70 mg/m\^2 days 1 and 2

   id

   FG000

   title

   Bendamustine (70 mg/m^2), MLN9708, Dexamethasone

2. description

   MLN9708 : 4 mg, days 1, 8, 15. Dexamethasone: 40 mg oral weekly. Bendamustine: 80 mg/m\^2 days 1 and 2

   id

   FG001

   title

   Bendamustine (80 mg/m^2), MLN9708, Dexamethasone

3. description

   MLN9708 : 4 mg, days 1, 8, 15. Dexamethasone: 40 mg oral weekly. Bendamustine: 90 mg/m\^2 days 1 and 2

   id

   FG002

   title

   Bendamustine (90 mg/m^2), MLN9708, Dexamethasone

periods

1. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         2

      3. group Id

         FG002

         num Subjects

         0

      type

      Physician Decision

   milestones

   1. achievements

      1. group Id

         FG000

         num Subjects

         4

      2. group Id

         FG001

         num Subjects

         8

      3. group Id

         FG002

         num Subjects

         6

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         3

      2. group Id

         FG001

         num Subjects

         6

      3. group Id

         FG002

         num Subjects

         6

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         1

      2. group Id

         FG001

         num Subjects

         2

      3. group Id

         FG002

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Dose Escalation Phase

2. drop Withdraws

   1. reasons

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         7

      3. group Id

         FG002

         num Subjects

         0

      type

      Physician Decision

   milestones

   1. achievements

      1. comment

         No subjects were started in this group as it was not the optimal dose.

         group Id

         FG000

         num Subjects

         0

      2. comment

         Subjects in Period 1 did not continue into Period 2. This is a new subject population.

         group Id

         FG001

         num Subjects

         20

      3. comment

         No subjects were started in this group as it was not the optimal dose.

         group Id

         FG002

         num Subjects

         0

      type

      STARTED

   2. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         13

      3. group Id

         FG002

         num Subjects

         0

      type

      COMPLETED

   3. achievements

      1. group Id

         FG000

         num Subjects

         0

      2. group Id

         FG001

         num Subjects

         7

      3. group Id

         FG002

         num Subjects

         0

      type

      NOT COMPLETED

   title

   Fixed Dose Phase

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice